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Summary
Objective: This study investigated the beneﬁts of the combination of interferential (IF) and patterned muscle stimulation in the treatment of
osteoarthritis (OA) of the knee.
Design: This was a multi-center, randomized, single-blind, controlled study with an independent observer. The study randomized 116 patients
with OA of the knee to a test or control group. The test group received 15 min of IF stimulation followed by 20 min of patterned muscle stim-
ulation. The control group received 35 min of low-current transcutaneous electrical nerve stimulation (TENS). Both groups were treated for 8
weeks. Subjects completed questionnaires at baseline and after 2, 4 and 8 weeks. Primary outcomes included the pain and physical function
subscales of the Western Ontario MacMaster (WOMAC) OA Index and Visual Analog Scales (VAS) for pain and quality of life.
Results: Compared to the control group, the test group showed reduced pain and increased function. The test group showed a greater
decrease in the WOMAC pain subscale (P¼ 0.002), function subscale (P¼ 0.003) and stiffness subscale (P¼ 0.004). More than 70% of
the test group, compared to less than 50% of the control group, had at least a 20% reduction in the WOMAC pain subscale. When analyzing
only patients who completed the study, the test group had a nominally signiﬁcant greater decrease in overall pain VAS. No signiﬁcant
between-group differences were observed in incidence of adverse events.
Conclusions: In patients with OA of the knee, home-based patterned stimulation appears to be a promising therapy for relieving pain, decreas-
ing stiffness, and increasing function.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) of the knee is the most common type of
arthritis. More than 10 million Americans have OA of the
knee1. Most people affected are older than 45 years. Path-
ologic changes in OA involve the progressive breakdown of
the articular cartilage within the joint2. The symptoms
include pain, swelling, bone spur formation and decreased
range of motion3. This causes disability and impairs
patients’ quality of life. Given the lack of a direct cure, treat-
ments for OA of the knee mainly focus on relieving pain, re-
ducing inﬂammation, decreasing stiffness, maintaining joint
mobility, and preventing further deformity4,5. Prescription
medicines such as acetaminophen, non-steroidal anti-
inﬂammatory drugs (NSAIDs), and opioids are used for1This paper contains conﬁdential information of RS Medical.
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865the relief of pain6e8. Intra-articular injections can achieve
short-term pain relief by lubricating the joint9. Regular low-
impact exercises as well as physical therapy help to main-
tain range of motion, muscle strength and general
health10,11. Unfortunately, pain medicines can have unde-
sirable side effects: many NSAIDs, such as aspirin, may
cause gastrointestinal distress, and narcotic painkillers
carry a risk of addiction. The beneﬁts of exercise can be
compromised by skeletal or muscle damage or injury, and
injections give only temporary relief of pain. Therefore, it
is necessary to explore additional treatments for OA of
the knee to better manage pain, save pain medication,
and restore knee function.
Electrical stimulation has been used for relief of pain for
many years, and its medical function has been accepted
since the gate control theory was introduced12. The purpose
of this randomized controlled study was to investigate the
beneﬁts of patterned stimulation vs conventional transcuta-
neous electrical nerve stimulation (TENS) in the treatment
of OA of the knee. The test group was treated with an inter-
ferential (IF) stimulation coupled with patterned muscle
stimulation. The control group was treated with low-current
866 F. X. Burch et al.: Patterned stimulation for OA of the kneeTENS. Since IF stimulation could provide long-lasting pain
relief, and patterned muscle stimulation could promote mo-
bility and restore function, this two-step treatment has the
potential to be a more efﬁcient treatment modality for OA
of the knee than single-step TENS stimulation.Materials and methodsETHICAL CONSIDERATIONSThe procedures followed were in accordance with the ethical standards of
21 CFR x50, 21 CFR x56, and ICH GCP.ENROLLMENTPatients were recruited by self-selection (advertisements) and by referral
from patient databases from four study sites in the United States. Of the 116
subjects, 32 were enrolled at an orthopedic clinic in Tucson, AZ; 41 were
enrolled at a clinical research organization (CRO) in San Antonio, TX; 32
were enrolled at a CRO in Portland, OR; and 11 were enrolled at a CRO
in Eugene, OR. Before taking part in the study, participants were asked to
read and sign an informed consent form approved by the central Institutional
Review Board (Quorum IRB, Seattle, WA). Patients who met all inclusion cri-
teria and did not violate any exclusion criteria were enrolled.
Criteria for inclusion were as follows: (1) evidence of OA in more than one
joint based on a physician’s assessment of patient-reported symptoms and
a differential diagnosis or radiographic evidence; (2) radiographic evidence
indicative of cartilage remaining in the entire knee and no bone-on-bone con-
tact within 6 months of enrollment; (3) OA pain present more days than not in
the knee chosen to receive electrical stimulation, and the overall pain VAS
rating 40 mm on a 100 mm line; (4) OA stiffness present more days than
not in the knee chosen to receive electrical stimulation, and typically lasting
less than 30 min; (5) agreement to follow the treatment plan and to use the
stimulation device; (6) older than 18; (7) signing the informed consent form.
Exclusion criteria were as follows: (1) hypersensitivity to electrostimula-
tion; (2) had intra-articular injections within 3 months to the knee to receive
electrostimulation; (3) if taking medications (e.g., oral steroids, non-steroidal
anti-inﬂammatories or acetaminophen), the dosage had not been stable for
at least 3 months prior to enrollment; (4) if taking chondroprotective supple-
ments (e.g., glucosamine and chondroitin sulfate), the dosage had not been
stable for at least 3 months prior to enrollment; (5) had pathologic processes
causing a structural defect in or instability of the knee at the knee to receive
electrostimulation (e.g., congenital defects, anatomical or mechanical defor-
mities, blunt trauma); (6) had cartilage-related surgery in the last 2 years;
(7) was pregnant or intended to become pregnant; (8) had known current
or remittent malignancy or cancer; (9) had implanted cardiac pacemaker or
deﬁbrillator; (10) had a body mass index (BMI)> 45; (11) had serious or un-
controlled systemic illness such as autoimmune disease, rheumatoid
arthritis, diabetes mellitus or renal failure; (12) concurrently used another
electrical stimulation device for treatment of knee symptoms; (13) previously
or concurrently used an RS Medical stimulation device; (14) was recently in
another clinical trial for medical devices or biologic agents; (15) had a rela-
tionship other than medical with principal investigators and their staff; (16)
had a relationship with another enrolled patient; (17) was unable to complete
the study or the case report forms.STUDY DESIGNThis study was designed as a multi-center, randomized, single-blind, con-
trolled study with an independent masked evaluator to test the efﬁcacy of
patterned stimulation in treatment of OA of the knee, whereby patients
were to receive one of two types of stimulation e IF plus patterned stimula-
tion (the test group) or low-current TENS (the control group). Patients were
blinded to the study hypothesis. Clinicians blinded to stimulation group as-
signment acted as independent masked observers and evaluators. Subjects
in both groups received a single session of 35-min unilateral electrical stim-
ulation daily for 8 weeks.
The baseline assessment included demographic data, OA symptoms and
prior treatments. Patients were also asked to answer questionnaires on pain,
OA-speciﬁc functioning, global impact of OA on life, and medication regimen.
After the baseline assessment, patients were issued an electrical stimulation
unit and instructed in the proper use of the device. The ﬁrst treatment session
was done under supervision in the clinic, and the rest were self-administered
at home.
Post-stimulation assessments were performed at 2, 4, and 8 weeks (2
days) after baseline, and patients were asked to answer the same question-
naires. A usage screening was set within 2 days of completion of the second
week of stimulation. Based on the usage information recorded on the device,
patients who did not complete a minimum of 50% of treatments during theﬁrst 2-week period were dropped from the study and considered screen
failures. The study was completed after the 8-week assessment.INTERVENTIONSThe device used to deliver the electrical stimulation was the RS-4i Stim-
ulator (RS Medical, 14001 SE First Street, Vancouver, WA). Stimulators
were pre-programmed to deliver either IF plus patterned muscle stimulation
or low-current TENS treatment. Two channels employing four reusable 2-
inch diameter cutaneous electrode pads were placed over the thigh and
back of the leg. For channel 1, one pad was placed over the vastus lateralis
(positive) and one over the vastus medialis (negative), and for channel 2, one
pad was placed over the proximal hamstrings (negative) and one over the
distal hamstrings (positive).
The test group stimulation session consisted of 15 min of IF stimulation
(step 1) followed by 20 min of patterned muscle stimulation (step 2). IF stim-
ulation had a base frequency of 5000 hertz (Hz) and a pre-modulated beat
frequency sweeping between 1 and 150 Hz. The electrode placement for
the IF step was the same as the patterned muscle stimulation placement,
and the IF was used primarily to decrease any discomfort that could possibly
be experienced during the patterned muscle stimulation mode. During IF
stimulation mode, patients were asked to increase the intensity until experi-
encing a gentle tingling feeling on skin, but not muscular contraction. The
muscle stimulation was a tri-phasic stimulation pattern based on electromyo-
graphic output of the normal activation timing and pattern of the quadriceps
and hamstrings during a high-level running activity. This pattern of stimula-
tion was speciﬁcally programmed into the device for the investigation. The
patterned muscle stimulation delivered 50 Hz impulses for 200 ms every
1500 ms. The waveform was a biphasic square wave with a ﬁxed amplitude
of 60 mA. Stimulation intensity was controlled by varying the pulse width,
which in this study ranged between 3.39 ms and 102.2 ms. Comparing the
output of most common muscle stimulators that have a ﬁxed pulse width
of 300 ms results in an equivalent amplitude range from 0.52 mA to
40.06 mA. The average output used by the subjects in the test group was
16.26 mA (the mode was 9.51 mA). Patients were instructed to increase
the intensity until feeling a mild but comfortable muscular contraction, and af-
ter 5 min, to turn up the intensity to produce a moderate to strong contraction
that could be tolerated without causing pain.
Each low-current TENS session consisted of 35 min of TENS. It was
delivered as a biphasic square wave with a 0.2 Hz frequency and a ﬁxed am-
plitude of 60 mA, with pulse width adjusted to provide a net output of 73 nC.
Delivered across 300 ms, this is equivalent to a peak output of 0.5 mA. The
stimulation might be perceived but would not produce a muscular contrac-
tion. Patients receiving low-current TENS were told the intensity was preset,
and adjustments had no effect on the actual current.OBJECTIVESThe study tested the difference in subjects with OA of the knee from base-
line to 8 weeks of treatment with patterned stimulation, compared to 8 weeks
of treatment with low-current TENS. The study evaluated changes in pain,
function, quality of life, use of breakthrough pain medication, adherence to
the study protocol, and safety of electrical stimulation.OUTCOME MEASUREMENTSThe Western Ontario MacMaster (WOMAC) OA Index is a validated
instrument designed speciﬁcally for the assessment of pain and function in
OA of the knee or hip. The WOMAC used in this study was the Likert version
3.1 standardized with English for an American population, consisting of 24
self-administrated questions that were answered for each item on a 5-point
Likert scale (none, mild, moderate, severe and extreme). It was reported
as three separate subscales: pain, physical function, and stiffness. The
WOMAC pain subscale had ﬁve questions scored 0e4 and was considered
invalid if more than one item was missing; hence, it had a range of 0 (no pain)
to 20 (maximal pain). In the event of a missing item, the remaining four items
were averaged and then multiplied by ﬁve. The WOMAC function subscale
had 17 questions scored 0e4 and was considered invalid if more than three
items were missing. It had a range of 0 (maximal function) to 68 (minimal
function). In the event of missing items, the remaining items were averaged
and then multiplied by 17. The WOMAC stiffness subscale had two items
scored 0e4 and was considered invalid if either was missing; hence it had
a range from 0 (no stiffness) to 8 (maximal stiffness). In the event of a missing
item, the score for the remaining item was multiplied by two.
Visual analog scale (VAS) lines were used for measuring overall pain in-
tensity and global impact of OA on quality of life. The VAS line for overall pain
rating was anchored at one end with ‘‘0’’ and the label ‘‘No Pain’’ and at the
other end with ‘‘100’’ and the label ‘‘Worst Pain Imaginable’’. VAS ratings
were provided for both knees. The VAS line for the quality of life rating
was anchored at one end with ‘‘0’’ and labeled ‘‘Very Poor’’ and at the other
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a mark on the line to report the intensity or quality of the sensation being
experienced.RANDOMIZATIONSubjects were assigned on an individual basis to the test group (IF plus
patterned muscle stimulation) or to the test group (low-current TENS).
They remained on the same allocation throughout the duration of their partic-
ipation in the study. Unblinded study physicians (or their authorized un-
blinded delegates) dispensed study devices, programmed to deliver either
IF plus patterned stimulation or low-current TENS, according to a sponsor-
provided random digits table with corresponding study groups. Blinded re-
searchers responsible for determining eligibility allocated the next available
number on entry into the trial, and then each subject collected an appropri-
ately programmed stimulator device from the unblinded physician or
delegate.BLINDINGAlthough subjects were informed that two treatment conditions were being
evaluated, they were not made aware of the hypotheses until their participa-
tion and debrieﬁng in the study was complete. Study physicians and study
coordinators responsible for evaluations and assessments were blinded to
treatment group allocations. Clinicians responsible for dispensing study de-
vices and instructing subjects on the use of study devices were unblinded
but did not serve in any other capacity during the study. Subjects were in-
structed to direct all questions about the study device to these unblinded
clinicians.STATISTICAL ANALYSESFor baseline comparisons, continuous variables were compared with Stu-
dent’s t test. Dichotomous variables were compared by Pearson’s chi-square
or Fisher’s exact test if the expected number in any cell was less than ﬁve.
Nominal categorical variables with greater than two response categories
were tested by Pearson’s chi-square.SAMPLE SIZEThe study was designed to have 80% power to detect a difference be-
tween the two treatment groups with an effect size [mean difference divided
by the standard deviation (SD)] of 0.6. Based on these assumptions, 45 pa-
tients per treatment group were required. To allow for dropouts or patients
with inadequate data, the planned enrollment was increased by one-third
to 60 patients per treatment group.PRIMARY ENDPOINTSPrimary endpoints include the following: (1) change from baseline in the
WOMAC pain subscale; (2) change from baseline in the WOMAC function
subscale; (3) change from baseline in VAS overall pain rating; (4) change
from baseline in VAS quality of life rating. Primary effectiveness analysis
was restricted to patients who passed the 2-week usage screening and
had at least one post-baseline visit. Patients who had no post-randomization
assessment or were missing a baseline assessment for any primary variable
were excluded from the analysis of that variable. Each primary endpoint was
analyzed by an analysis of variance (ANOVA) that included the effects of
treatment group, study center, and the corresponding baseline assessment.
Since there were four co-primary endpoints, a Bonferroni correction was em-
ployed; hence, each co-primary endpoint was tested using a two-sided test
at a signiﬁcance level of 0.0125 (0.05/4). All results were shown as SAS
LSMEANS adjusted for the variables in the model and two-sided 98.75%
conﬁdence intervals (CIs) on their difference.
As a secondary analysis of each of the primary endpoints, all baseline
variables that were nominally statistically signiﬁcantly different between
treatment groups were added to the primary model to assess their impact.
This was done by a stepwise regression in which at each step the baseline
variable with the highest P value was excluded until all baseline variables
remaining in the model had a P value< 0.10.SECONDARY ENDPOINTSSecondary endpoints include the following: (1) mean change from base-
line to each scheduled visit for each primary endpoint to demonstrate the
time course of effect; (2) frequency of patients reporting 20% or more im-
provement for each of the primary outcomes; (3) change in WOMAC stiff-
ness subscale after 8 weeks of stimulation; (4) use of breakthroughmedication for pain; (5) adherence to treatment protocol; (6) safety of electri-
cal stimulation. Continuous secondary endpoints were analyzed using the
same statistical model described for the primary variables. Dichotomous
endpoints were analyzed by a logistic regression that included the effects
of treatment group, study center, and the corresponding baseline assess-
ment. Results for continuous variables were shown as least squares means
adjusted for the variables in the model and two-sided 95% CIs on their differ-
ence. Results for dichotomous variables were presented as odds ratios
estimated from the logistic regression and their two-sided 95% CIs. All
P values are reported as two-sided nominal values.
Adverse events were recorded as the number and percentage of patients
reporting each event. Comparisons were made between treatment groups in
adverse event rates by Fisher’s exact test.
All statistical analyses were completed using the SAS/STAT software,
version 9.1.ResultsPARTICIPANTS’ PROGRESSIONFrom a pool of 136 individuals, a total of 116 met the
screening criteria and were randomized (Fig. 1). Fifty-seven
patients in the test group and 59 patients in the control
group were given a baseline assessment. All 116 random-
ized patients were included in the safety analysis.
Seven patients (three in the test group and four in the
control group) used the stimulation device for less than
50% of the days during the ﬁrst 2-week period and were
dropped from the study as screen failures. Therefore, these
patients were excluded from all analyses of effectiveness.
The remaining 109 patients (54 in the test group and 55
in the control group) were considered eligible for effective-
ness analysis. Of the 109 patients, 106 (53 in each group)
had at least one post-baseline visit and were included in
the effectiveness analyses of primary endpoints.
Six patients (three in each group) dropped out of the
study between the Week 2 and Week 4 assessments,
and another two (one in each group) dropped out between
the Week 4 and Week 8 assessments due to an adverse
event, lack of effectiveness, loss to follow-up or patient
decision. A total of 101 patients completed the 8-week
study (Fig. 1).RECRUITMENTSubject recruitment began on January 22, 2004. The ﬁrst
subject was enrolled on February 17, 2004, and the last
subject was enrolled on March 1, 2005. The last subject
completed participation in the study on April 25, 2005. Par-
ticipants attended clinic visits at baseline and again after 2
weeks, 4 weeks, and 8 weeks.
Subject characterization
Table I summarizes baseline demographic data, OA
symptoms, and prior treatment for all patients eligible for
effectiveness analysis. The two randomized groups were
comparable at baseline, except for height, BMI, prior use
of acupuncture, and steroid injections (P values< 0.05).
The mean age was approximately 61 years for both groups,
with the majority being female, Caucasian, and overweight
(BMI> 29). Nearly half of the participants were retirees.
Both groups had been treated for OA of the knee for an
average of 8 years. A greater proportion of patients in the
control group had tried acupuncture and steroid injections
than those in the test group.
Although not a criterion for study entry, eligibility of sub-
jects was veriﬁed with the KellgreneLawrence scale,
a method for measuring the presence and severity of OA.
An independent facility and blinded physician scored all
Subjects met criteria and
randomized
N=116
Ineligible patients
N=20
Individual screened
N=136
IF Plus Patterned Stimulation
(test group)
N=57
Low-current TENS 
(control group)
N=59
Failed week 2 screen
N=3
Completed baseline
assessment
N=57
Failed week 2 screen
N=4
Completed baseline
assessment
N=59
Dropped out
N=3
Eligible and completed
week 2 assessment
N=54
Dropped out
N=3
Eligible and completed
week 2 assessment
N=55
Dropped out
N=1
Completed week 4
assessment
N=51
Dropped out
N=1
Completed week 4
assessment
N=52
Completed week 8
assessment
N=50
Completed week 8
assessment
N=51
Fig. 1. Participants’ progression.
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subjects were determined to have a KellgreneLawrence
score of at least 1 for OA of the knee. These scores were
also analyzed for their impact on the statistical signiﬁcance
of the three WOMAC subscales. It was determined that
there was no signiﬁcant difference in the baseline Kellgrene
Lawrence scores between treatment groups and that there
was no statistical inﬂuence of these scores on the analysis
of the WOMAC indices.WOMAC INDICES OF PAIN, FUNCTION AND STIFFNESSTables IIeIV list the baseline mean and mean change
from baseline to last visit for each of the WOMACsubscales. Lower scores are indicative of less impact of
OA. The two treatment groups had comparable baseline
means for each of the WOMAC subscales (P values> 0.5).
After 8 weeks of treatment, patients in the test group had
signiﬁcantly greater reduction than patients in the control
group in the WOMAC pain subscale (3.98 vs 1.90;
P¼ 0.002), physical function subscale (12.86 vs 6.74;
P¼ 0.003), and stiffness subscale (1.53 vs 0.74;
P¼ 0.004), suggesting that IF plus patterned muscle stimu-
lation was more efﬁcient than low-current TENS in relieving
pain, increasing function and decreasing stiffness.
Stepwise regression analysis showed the four imbal-
anced baseline variables (height, BMI, prior use of acu-
puncture and steroid injections in Table I) had no impact
Table I
Patient characterization
Test group
(N¼ 54)
Control group
(N¼ 55)
P value
Females: N (%) 36 (66.7%) 43 (78.2%) 0.18
Age
MeanSD 62.6 10.5 60.8 11.4 0.37
Range 38e87 22e86
Weight (lb)
MeanSD 185.6 39.1 193.1 41.3 0.33
Range 112e288 114e298
Height (inch)
MeanSD 66.7 3.2 65.4 3.6 0.040
Range 60e74 58e74
BMI (kg/m2)
MeanSD 29.3 5.4 31.7 5.8 0.025
Range 19.9e41.4 20.0e44.1
Race
American
Indian or
Alaska native
0 (0%) 2 (3.6%) 0.62*
African American 1 (1.9%) 2 (3.6%)
Caucasian 39 (72.2%) 42 (76.4%)
Asian 0 (0%) 2 (3.6%)
Other 14 (25.9%) 7 (12.7%)
Work status
Full time 12 (22.2%) 12/54 (22.2%) 0.97
Part time 10 (18.5%) 9/54 (16.7%)
Retired 26 (48.2%) 27/54 (50.0%)
Unemployed 5 (9.3%) 4/54 (7.4%)
Medical disability 1 (1.9%) 2/54 (3.7%)
Knee treatedy
Left 22/53 (41.5%) 19/53 (35.9%) 0.55
Right 31/53 (58.5%) 34/53 (64.2%)
Length of treatment (years)
MeanSD 8.0 7.9 8.6 7.8 0.73
Range 0e30 0e29
OA in other joints: n (%) 33 (61.1%) 34 (61.8%) 0.94
Prior treatments for OA symptoms
OTC analgesic 50 (92.6%) 52 (94.6%) 0.72
NSAIDs 35 (64.8%) 38 (69.1%) 0.64
Opioid 27 (50.0%) 20 (36.4%) 0.15
Oral steroid 9 (16.7%) 16 (29.1%) 0.12
Supplements 37 (68.5%) 42 (76.4%) 0.36
Vitamins 37 (68.5%) 46 (83.6%) 0.06
Physical therapy 27 (50.0%) 31 (56.4%) 0.51
Acupuncture 4 (7.4%) 17 (30.9%) 0.002
Steroid injection 14 (25.9%) 25 (45.5%) 0.034
*Caucasian vs non-Caucasian.
yPatients with at least one post-baseline visit.
Table II
Mean baseline and change from baseline to the last visit in
WOMAC pain subscale
Test group
(N¼ 52)
Control group
(N¼ 53)
Baseline
MeanSD 9.6 3.3 9.3 3.5
Range 2e18 2e18
P value 0.61
Change from baseline*
Mean 3.98 1.90
Difference (98.75% CI) 2.09 (0.60e3.57)
P value 0.002
*Adjusted for study center and baseline assessment.
Table III
Mean baseline and change from baseline to the last visit in
WOMAC function subscale
Test group
(N¼ 52)
Control group
(N¼ 53)
Baseline
MeanSD 32.8 11.6 33.7 12.6
Range 8e61 6e65
P value 0.70
Change from baseline*
Mean 12.86 6.74
Difference (98.75% CI) 6.12 (1.57e10.66)
P value 0.003
*Adjusted for study center and baseline assessment.
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and function), and the difference between treatment groups
remained statistically signiﬁcant.
Four patients (two in each group) had missing values and
were excluded from the primary effectiveness analyses of
WOMAC pain and function. Two sensitivity analyses
showed that neither inputting a value of zero nor the most
conservative value (the worst score in the test group and
the best score in the control group) as the change from
baseline changed the statistical signiﬁcance. This demon-
strates that the loss of four patients due to missing values
did not impact the results enough to compromise theconclusion of superiority of the test group over the control
group in the WOMAC pain and function subscales.
Two secondary effectiveness analyses, which included
only patients who completed the study, were performed
for the WOMAC pain and function scale. The ﬁrst analysis
assessed the interaction of treatment group by time.
The mean change from baseline to each scheduled visit
for the two treatment groups were contrasted (Fig. 2). The
results showed that at the week 2 visit, patients in the test
group already had signiﬁcantly greater reduction than the
control group in WOMAC subscales of pain (2.50 vs 1.08;
P¼ 0.008) and function (7.74 vs 4.14; P¼ 0.03), suggest-
ing that the test group started to show a stronger beneﬁcial
effect after only 2 weeks of stimulation. The second analy-
sis compared the frequency counts of patients who reported
20% or more improvement in two WOMAC primary
outcomes. The results showed that a higher percentage
of patients in the test group had improvement for WOMAC
subscales of pain (71.2% vs 49.1%; P¼ 0.023) and
function (65.4% vs 45.3%; P¼ 0.030) than patients in the
control group. Therefore, the secondary effectiveness
analyses result mirrored the primary analyses in favor of
the test group.PAIN AND QUALITY OF LIFE VAS RATINGSTables V and VI list the baseline mean and mean change
from baseline to last visit for the overall pain VAS and qual-
ity of life VAS. Lower scores indicated less pain or less
impact of OA on quality of life. The two treatment groups
had comparable baseline means for both VAS ratings.
Table IV
Mean baseline and change from baseline to the last visit in
WOMAC stiffness subscale
Test group
(N¼ 53)
Control group
(N¼ 53)
Baseline
MeanSD 4.49 1.25 4.51 1.37
Range 2e7 2e8
P value 0.94
Change from baseline*
Mean 1.53 0.74
Difference (95% CI) 0.80 (0.26e1.34)
P value 0.004
*Adjusted for study center and baseline assessment.
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870 F. X. Burch et al.: Patterned stimulation for OA of the kneeThe mean changes from baseline to last visit in quality of life
VAS rating were similar between the two groups (18.17 vs
18.16; P¼ 0.99). Patients in the test group had a greater
decrease in the overall pain VAS (27.91 vs 23.19;
P¼ 0.29) at their last visit, but the difference between treat-
ment groups did not achieve statistical signiﬁcance. How-
ever, if only patients who completed the study (49 in test
group and 50 in control group) were included for the analy-
sis, the difference between groups in mean change from
baseline increased from 4.71 to 9.40 for overall pain VAS
rating and achieved statistical signiﬁcance (P¼ 0.038).
Secondary effectiveness analyses for treatment group by
time interaction or frequency counts of patients who
achieved 20% or more improvement did not show statistical
signiﬁcance.se
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aCompliance with the treatment was assessed by the
difference between the number of days each patient was
in the study and the number of days that he/she used the
device. This was only done for patients who completed the
study. 94.1% of the 101 subjects who completed the study
used the device on at least half of the days after the initial
2-week compliance screening period. Of the six non-compliant
subjects (two from the test group and four in the control
group), one (from the control group) did not use the device
at all after the 2-week compliance screening period.Fig. 2. Scores of WOMAC subscales of pain (A), function (B), and
stiffness (C) at each scheduled visit.USE OF BREAKTHROUGH MEDICATIONUse of breakthrough medication for pain was reported at
week 4 and 8 assessments. Very few patients (one in the
test group and ﬁve in the control group) used breakthrough
medication for pain, and the results were comparable be-
tween the two treatment groups.SAFETY ANALYSISAdverse events categories included skin irritation, skin
burns, muscle soreness, electrical shock, and unanticipated
adverse events. Adverse events reported in this study were
mild. The rate was low and very similar in the two treatment
groups: there were ﬁve adverse events in the test group and
nine adverse events in the control group. One of the
adverse events (in the control group) was rated as probably
related to the study device. The patient reported muscle
soreness, which did not require treatment and was resolved
after 1 day. The patient completed the study as planned.Discussion
The study assessed the beneﬁts of a home-based elec-
trostimulation treatment combining IF and patterned muscle
stimulation in treatment of OA of the knee. Low-current
TENS was applied as a control. WOMAC subscales of
pain, stiffness, and function and VAS for overall pain and
quality of life were measured at various points during the
8-week study. Patients treated with IF plus patterned stimu-
lation reported decreases in pain and knee stiffness and in-
creases in physical function at the end of the study.
Improvement of the three WOMAC subscales in the test
group was signiﬁcantly greater than in the control group.
We also observed that patterned stimulation started to
show stronger effects in relieving pain and improving func-
tion than low-current TENS after only 2 weeks of treatment.
Table V
Mean baseline and change from baseline to the last visit in overall
pain VAS
Test group
(N¼ 53)
Control group
(N¼ 53)
Baseline
MeanSD 63.7 13.2 60.7 15.4
Range 30e86 11e100
P value 0.26
Change from baseline*
Mean 27.91 23.19
Difference (98.75% CI) 4.71 (5.37e14.80)
P value 0.29
*Adjusted for study center and baseline assessment.
871Osteoarthritis and Cartilage Vol. 16, No. 8Patients treated with patterned stimulation also had
a greater decrease in the VAS overall pain assessment at
their last visit, although the difference did not achieve statis-
tical signiﬁcance. It was not expected that VAS overall pain
and quality of life would achieve statistical signiﬁcance, be-
cause they are tests for general purposes, while WOMAC is
a test speciﬁcally designed for OA of the knee.
In our study, patients in the test group, who received IF
plus patterned muscle stimulation, reported greater de-
creases in pain. Seventy percent of the patients in the
test group had 20% or more reduction in the WOMAC
pain subscale, and the patient percentage was signiﬁ-
cantly higher (P¼ 0.023) than in the control group. After
only 2 weeks of treatment, the test group already started
to show this greater pain relief than the control group
(P¼ 0.008). These signiﬁcant results may in part be
due to IF stimulation. IF stimulation delivers current
more deeply than conventional TENS13,14. In our study,
IF stimulation was applied prior to patterned muscle stim-
ulation, and this provided better pain management and
allowed the underlying OA condition to be more comfort-
ably treated with patterned muscle stimulation.
In addition to improvement on the pain subscale, patients
in the test group had signiﬁcantly greater improvement in
the WOMAC physical function subscale (P¼ 0.003) and
stiffness subscale (P¼ 0.008) than patients in the control
group. The difference was perceived after only 2 weeks of
treatment (P¼ 0.03 for function). The improvement of func-
tion and stiffness was likely the result of patterned muscle
stimulation, with a possible contribution from better pain
management. Muscle stimulation excites motor neurons
and causes a muscle contraction. The muscle stimulation
used in this study was based on normally occurring nerveTable VI
Mean baseline and change from baseline to the last visit in quality
of life VAS
Test group
(N¼ 52)
Control group
(N¼ 51)
Baseline
MeanSD 53.3 24.1 57.8 23.8
Range 0e95 16e100
P value 0.93
Change from baseline*
Mean 18.17 18.16
Difference (98.75% CI) 0.01 (9.32e9.35)
P value 0.99
*Adjusted for study center and baseline assessment.and muscle timing patterns and consisted of tri-phasic
bursts of electrical impulses that were delivered in a timing
conﬁguration replicating electromyographic patterns of
movement associated with agonist/antagonist pairs of mus-
cles (the quadriceps and hamstrings) during a high-level
running activity. Subjects adjusted stimulation intensity to
a comfortable level that generated low-level contractions
(stimulation amplitude was ﬁxed at 60 mA, and subjects ad-
justed the stimulation intensity by varying pulse width). By
using the same inter-muscular sequencing as the body’s
natural neurophysiological electrical impulses, patterned
stimulation re-educated disused and weak muscles by facil-
itating normal movement. This should promote local blood
circulation, increase range of motion and strength, prevent
or retard disuse atrophy, and restore knee function15e17.
In this study, electrodes were placed on patients’ vastus
lateralis, vastus medialis, and hamstrings, as the primary
functions of the quadriceps and hamstrings are knee exten-
sion (straightening the knee) and knee ﬂexion (bringing the
heel toward the buttocks). By contracting and exercising
the muscles that mainly control knee movement, patterned
stimulation can decrease knee stiffness and increase range
of motion. It is the authors’ opinion that, by mimicking the
body’s natural gait pattern, patterned stimulation improves
the quality and viscosity of synovial ﬂuid in the knee. Pat-
terned stimulation is a neurofacilitative treatment that may
correct the cumulative effects of pain-induced guarding.
This proposed mechanism is supported by a study con-
ducted in dogs with established OA in one of the two stiﬂe
joints to examine the effects of patterned stimulation on
the quality and viscosity of synovial ﬂuid. After 14 weeks of
treatment with patterned stimulation, synovial ﬂuid analysis
revealed changes in synovial ﬂuid markers, including a trend
for decreasing sulfated glycosaminoglycan (sGAG), and
a 20% decrease in soluble collagen within the synovium,
compared to the control group (MS Shih, D.V.M., Ph.D.,
unpublished data, 2007). Durability of treatment in a carry-
over effect is unknown and warrants further study.
Our results were consistent with other published research
that proved the therapeutic function of muscle stimulation in
increasing muscle strength and improving functional perfor-
mance. Delitto et al. compared electrical muscle stimulation
vs voluntary exercise in strengthening thigh musculature
after anterior cruciate ligament surgery18. Their results
showed that patients in the electrical muscle stimulation
group who ﬁnished the 3-week training regimen achieved
higher percentages of both extension and ﬂexion torque
compared to patients in the voluntary exercise group. Dur-
mus et al. tested the effects of electrical muscle stimulation
on pain, disability, and quadriceps strength in older female
patients with OA of the knee, with biofeedback-assisted iso-
metric exercises as a control19. Their results showed that
electrical muscle stimulation was as effective as voluntary
exercise in improving pain, physical function, and stiffness
scores after therapy. Talbot et al. tested the feasibility of
neuromuscular stimulation to increase quadriceps femoris
(QF) strength in older adults with symptomatic OA of the
knee20. Their results showed that patients in neuromuscular
stimulation plus education group had increased QF muscle
strength, physical activity and function performance than
patients in the education-only group.
Some pain relief was seen in the control group using low-
current TENS, but the change was not as substantial as
when using IF plus patterned stimulation. TENS has been
used clinically to produce analgesia and anesthesia for
acute or chronic pain relief21. However, unlike high-
frequency IF stimulation, TENS cannot overcome the high
872 F. X. Burch et al.: Patterned stimulation for OA of the kneecapacitive resistance of skin22, and this limits its depth of
penetration and efﬁcacy in pain relief. We used 0.5 mA out-
put, which was at the lower range of TENS and did not
cause muscle contraction; hence, it was not expected that
low-current TENS would generate the same curative effect
on knee mobility and function as patterned stimulation.
The goals of treating OA of the knee are to control symptoms
and to restore function. Our study showed that a two-step
stimulation combining IF and patterned muscle stimulation
in a single treatment appears to be a promising intervention
for relieving pain, decreasing knee stiffness and improving
function. To investigate further the effectiveness of this
combination of stimulation for OA of the knee, future studies
should follow subjects for several weeks or months after the
end of treatment to evaluate the post-treatment durability of
patterned stimulation. Future studies should also include ki-
nematic evaluations to further evaluate the effect of pat-
terned stimulation on functional walking capabilities. It
would also be beneﬁcial to compare the efﬁcacy of pat-
terned stimulation against controls based on other standard
therapies, including physical therapy and pain medications.
Our results suggest that patterned stimulation has the po-
tential to be a more effective treatment modality than con-
ventional single-step TENS for OA of the knee. Patterned
stimulation treatment is a non-invasive, non-habit forming,
cost-effective rehabilitative modality. It is ideal for patients
who have painful OA conditions, stiff joints from disuse of
muscles, or difﬁculty exercising.Conﬂict of interest
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